ACRS — Aclaris Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1557746 ·
Last close
$3.38
Market Cap
$536.11M
52W High
$6.60
52W Low
$2.34
ADV30
3,335,158
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 1,629,000 | 176,000 | -23,938,000 | -21,505,000 | 179,693,000 | 19,167,000 | 55,112,000 |
| Mar 2026 | 1,996,000 | 208,000 | -22,192,000 | -19,824,000 | 198,720,000 | 28,660,000 | 55,071,000 |
| Dec 2025 | 1,295,000 | -174,000 | -22,334,000 | -19,795,000 | 160,460,000 | 19,960,000 | 57,378,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-62,059,000
Investing CF
$3,530,000
Financing CF
$52,294,000
CapEx
$-118,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.58
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,009,113,000
Inventory
—
Receivables
$4,680,000
ST Investments
$72,389,000
EBIT TTM
$-85,513,000
Pretax Income TTM
$-75,738,000
Interest Exp TTM
—
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$8,219,000
EBITDA
$-85,525,000
Free Cash Flow
$-41,970,624
Enterprise Value
$451,985,920
Total Cash
$91,556,000
Total Debt
$1,850,000
Shares Out
158,612,149
Trailing EPS
$-0.59
Book Value
$0.85
ROE
-59.1%
ROA
-29.0%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 7,826,000 | -74,075,000 | -64,923,000 | 160,460,000 | 57,378,000 | 103,082,000 | -47,113,000 |
| Dec 2024 | 18,720,000 | -52,527,000 | -132,065,000 | 220,327,000 | 64,773,000 | 155,554,000 | -20,075,000 |
| Dec 2023 | 31,249,000 | -116,314,000 | -88,481,000 | 197,405,000 | 40,226,000 | 157,179,000 | -78,325,000 |
| Dec 2022 | 29,752,000 | -85,154,000 | -86,908,000 | 254,596,000 | 56,975,000 | 197,621,000 | -67,567,000 |
TTM Snapshot
Revenues TTM
$8,219,000
NetIncome TTM
$-75,738,000
OpCashFlow TTM
—
Assets (Latest)
$179,693,000
Forward EPS
$-0.72
Max Pain — expiry 2026-12-18
max pain strike: $3.00 · spot: $3.50 · call oi: 7,290 · put oi: 2,407
Expected Move to 2026-12-18:
±$0.68
(19.29%) —
implied range
$2.83 –
$4.17
· ATM straddle on $3.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HELP | Helus Pharma Inc. | $526.03M | $7.20 | — |
| EVO | Evotec SE | $525.98M | $1.48 | — |
| AVBP | ArriVent BioPharma, Inc. | $552.92M | $10.69 | — |
| ANL | Adlai Nortye Group Ltd. | $556.80M | $9.48 | — |
| ZVRA | ZEVRA THERAPEUTICS, INC. | $559.34M | $9.40 | — |
News headlines (Yahoo Finance, 1h cache)
Aclaris stock falls after atopic dermatitis trial fails
2026-11-16 16:52 · Yahoo
Aclaris Therapeutics’ mAb fails in Phase II eczema trial
2026-11-16 14:58 · Yahoo
Why is Aclaris Therapeutics Stock Trading Lower on Monday?
2026-11-16 14:27 · Yahoo
Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)
2026-11-16 08:30 · Yahoo
Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)
2026-11-16 08:28 · Yahoo
Aclaris Therapeutics to Participate in the Jefferies Global Healthcare Conference
2026-11-12 12:30 · Yahoo
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Beats Revenue Estimates
2026-11-05 13:35 · Yahoo
Aclaris: Q3 Earnings Snapshot
2026-11-05 12:15 · Yahoo
Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update
2026-11-05 11:59 · Yahoo
Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1b
2026-10-27 22:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.